animals2 and reduces gall stone recurrence in man after dissolution therapy.3 Mucus biosynthesis in human gall bladder mucosal explants is inhibited by aspirin in vitro. 4 We have studied the effects of aspirin in vivo. Fifty five patients with functioning gail bladder and stones have been randomised, 27 to group 1 (aspirin EC 300 mg once daily for seven days before cholecystectomy) and 28 to group 2 (controls). Gall bladder bile composition was analysed and mucus synthesis rates measured using 3H-glucosamine incorporation into mucosal explants cultured for 24 hours. 4 Patient age, sex, and gall bladder histology were similar in both groups. There were no differences in stone composition, gall bladder bile calcium concentration, cholesterol saturation and cholesterol nucleation time. The mean 3H-glucosamine incorporation in aspirin treated patients was 1347 fmol/g wet weight as compared with 2008 fmol/g wet weight in controls (95% confidence interval 222-1100, p<0 005, unpaired t test). This reduction in biosynthesis was associated with gall bladder bile mucus concentrations of 7.6 mg/ml in patients and 7.1 mg/ml in controls (ns) . Treatment with aspirin led to a significant reduction in mucus biosynthesis by the gall bladder mucosa. This action is consistent with a role for aspirin in the prevention of The choice of aspirin dose was based on the known safety and efficacy of 300 mg aspirin EC/ day while the decision to treat the patients for seven days before cholecystectomy was made to improve compliance and facilitate administration of the trial.
ETHICAL CONSIDERATIONS
Informed consent was obtained from each patient and ethical approval for the study was granted by both the Newcastle and Northumberland Ethical Committees.
LABORATORY METHODS

MUCUS GLYCOPROTEIN BIOSYNTHESIS IN MUCOSAL EXPLANTS
Mucosal explants of freshly excised gall bladder were grown for 24 hours in tissue culture.27
Glucosamine hydrochloride, D-[6-3H(N)]-, with a specific activity of 1110 0 GBq/mmol, was used to label macromolecules. 3H-glucosamine was used at a concentration of 74 KBq/ml in the tissue culture medium. Total 3H-glucosamine incorporation into mucin was measured after removal of protein and low molecular weight radioactive material by papain digestion (72 hours) and exhaustive dialysis against distilled water (144 hours). Papain digestion is an effective method for isolation of mucus glycoprotein. After digestion, dialysis removes protein and non-glycosylated regions of protein core, leaving behind non-dialysable, mucus glycoprotein. 28 Glucosamine incorporation into the glycoprotein component of mucin was confirmed by fractionation on a caesium chloride density gradient29 and by gel filtration on sepharose 4B. All radioactive mucin fractionated in a peak coincident with purified, papain digested human gall bladder mucin. Gall bladder mucosa, killed in liquid nitrogen was used as a control to check for non-specific interactions between the tissue and 3H-glucosamine.
MUCUS GLYCOPROTEIN CONTENT OF GALL BLADDER BILE
Quantitation of mucus glycoprotein was undertaken using a modified 'Slotblot' technique. 30 After blotting samples of bile onto nitrocellulose membranes, mucus glycoprotein was visualised using the periodic acid/Schiff reaction.3' Colour yeild was then measured using a scanning densitometer (Shimadzu, Japan). Results were compared with those obtained by measuring glycoprotein after purification of the mucin by the traditional method of fractionation on a caesium chloride density gradient and showed close correlation.
CHOLESTEROL
The cholesterol concentration in bile was measured using the enzymatic method first described by Roda32 and modified by Bolton.33 Briefly, this involved diluting samples of gall bladder bile obtained by needle puncture at laparotomy 1 in 10 with isopropanol and incubating the diluted sample with three enzymes. Sequential treatment of bile with catalase, cholesterol esterase and cholesterol oxidase (Sigma, UK) produces cholestenone and hydrogen peroxidase. The hydrogen peroxide is then used as an oxidising agent in a colorimetric assay.
The cholesterol content of gall stones was measured by crushing the dried stones with a pestle and mortar, extracting the cholesterol in isopropanol and quantifying it as described above. 
Results
Of 73 patients randomised, 18 were withdrawn from the study (Table I) . Patients who had fibrotic oedematous or acutely infected gall bladders were withdrawn from the study because it was not possible to conduct explant culture. Of the 55 patients who were suitable for further study, 27 were randomised to the aspirin treated group and 28 to the control group. The male to female ratio, mean age and mean duration of symptoms were similar in the two groups (Table II) . Gall bladder histology was also comparable in both groups.
MUCUS GYLCOPROTEIN SYNTHESIS BY GALL BLADDER MUCOSA
Gall bladder mucus biosynthesis, as measured by 3H-glucosamine incorporation, was significantly less in aspirin treated patients than in the untreated controls. Gall bladder explants from controls incorporated a mean of 2008 fmol/g wet weight (SD 892) of 3H-glucosamine as compared with 1347 fmol/g wet weight (SD 722) in aspirin treated patients (p<0005, 95% confidence interval for the difference 222 to 1100, unpaired t test), (Figure) . Incorporation of 3H-glucosamine (Table III) . Cholesterol saturation, calcium concentration and stone composition were also similar in the two groups (Table III) .
SIDE EFFECTS AND COMPLICATIONS
There was no postoperative morbidity in the control group. Two patients in the aspirin treated group had complications. Broomfield. Our study has shown inhibition of gall bladder mucin biosynthesis using aspirin at a dose of 300 mg/day. At this dose we have failed to show significant prolongation of cholesterol nucleation time. Longterm treatment with aspirin at a dose of 300 mg/day has been shown to be safe in asymptomatic subjects who took part in The Physicians Health Study43 and the UK TIA study. 44 If future studies show prolongation of cholesterol nucleation time as a consequence of longterm treatment with aspirin at a dose between 300 mg/day and 1200 mg/day, there might be a role for the drug in the prevention of gall stones among high risk groups. 
